Analyst
TD Cowen
Equibles does not estimate personal net worth.
Yaron Werber is recorded as Analyst at TD Cowen. Yaron Werber has spoken on 8 earnings calls and 2 other investor events across 8 companies, most recently for Ultragenyx Pharmaceutical Inc. on August 19, 2026. Those appearances were for Legend Biotech Corp (LEGN), BioNTech SE (BNTX), Ultragenyx Pharmaceutical Inc. (RARE), Roivant Sciences Ltd. (ROIV), BeOne Medicines Ltd. (ONC) and 3 other companies. The companies whose calls Yaron Werber spoke on are classified in the Healthcare sector.
“Let me add that this is really a terrific milestone, and congrats. I know this is years and years of work. I have maybe just a couple of questions.”
“And congrats on moving toward the ISD within Vivo in China. I have maybe just a two-part question on the tax rate in China. That would be applied, it sounds like, to the global profits from now on.”
“I don't think this has been talked about yet, but for the Brepo launch, can you maybe talk about a few launch analogs that you're assessing right now, either patient curve or market share curve?”
“Question, PRNP5 is a really important target, and you're the lead essentially with a brain penetrant molecule. So it sounds like you're going to have data in lung cancer at ESMO.”
“I have maybe kind of a dual-part question. The first one, meningioma, stellar 201. So it's really encouraging to see how fast it enrolled. And we've seen in these areas that a single-arm phase two can lead to approval.”
TD Cowen
Analyst
Source not stated
LEGN
Biotechnology · Healthcare
BNTX
Biotechnology · Healthcare
EXEL
Biotechnology · Healthcare
